Author

Thomas J. Borody

ESOMEPRAZOLE VERSUS VONOPRAZAN - BASED THERAPIES FOR HELICOBACTER PYLORI ERADICATION: A RETROSPECTIVE CLINICAL STUDY
ESOMEPRAZOLE VERSUS VONOPRAZAN - BASED THERAPIES FOR HELICOBACTER PYLORI ERADICATION: A RETROSPECTIVE CLINICAL STUDY

PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES
PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES

CELL WALL DEFICIENT (CWD) MYCOBACTERIA IN WBCS AND ILEAL CROHN’S TISSUES
CELL WALL DEFICIENT (CWD) MYCOBACTERIA IN WBCS AND ILEAL CROHN’S TISSUES

Thomas J. Borody  et al.

PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES
PROLONGED REMISSION OF ULCERATIVE COLITIS USING FAECAL MICROBIOTA TRANSPLANTATION - A CASE SERIES

Thomas J. Borody  et al.

ESOMEPRAZOLE VERSUS VONOPRAZAN – BASED THERAPIES FOR HELICOBACTER PYLORI ERADICATION: A RETROSPECTIVE CLINICAL STUDY
ESOMEPRAZOLE VERSUS VONOPRAZAN – BASED THERAPIES FOR HELICOBACTER PYLORI ERADICATION: A RETROSPECTIVE CLINICAL STUDY

Thomas J. Borody  et al.

AN INVESTIGATIONAL ORAL MICROBIOME DRUG, CP101, FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL (PRISM3)
AN INVESTIGATIONAL ORAL MICROBIOME DRUG, CP101, FOR THE PREVENTION OF RECURRENT C. DIFFICILE INFECTION: A RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL (PRISM3)

Thomas J. Borody  et al.

Item 1 - 6 / 6
1